Pure Global

KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial - Trial NCT06097793

Access comprehensive clinical trial information for NCT06097793 through Pure Global AI's free database. This Phase 1 trial is sponsored by Kousai Bio Co., Ltd. and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06097793
Phase 1
Not yet recruiting
biological
Trial Details
ClinicalTrials.gov • NCT06097793
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

Study Focus

Nasopharyngeal Carcinoma

KSD-101

Interventional

biological

Sponsor & Location

Kousai Bio Co., Ltd.

Wuhan, China

Timeline & Enrollment

Phase 1

Nov 01, 2023

Dec 31, 2025

12 participants

Primary Outcome

Safety endpoint

Summary

The main purpse of this study is to evaluate the safety of KSD-101 in patients with
 EBV-associated Nasopharyngeal Carcinoma,to evaluate the initial clinical outcomes and
 evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated
 Nasopharyngeal Carcinoma

ICD-10 Classifications

Malignant neoplasm of nasopharynx
Malignant neoplasm: Nasopharynx, unspecified
Malignant neoplasm: Overlapping lesion of nasopharynx
Benign neoplasm: Nasopharynx
Malignant neoplasm: Posterior wall of nasopharynx

Data Source

ClinicalTrials.gov

NCT06097793

Non-Device Trial